Cambrex公司_上海生物_拜力生物_新浪博客

来自 : 新浪博客 发布时间：2021-03-25

Cambrex Corporation is an innovative life sciences companyproviding products, services and technologies to accelerate thedevelopment and commercialization of small moleculetherapeutics.Cambrex公司We offer a variety of technology-driven products and services forgeneric and branded pharmaceuticals:Advanced intermediatesDrug delivery productsCambrex公司Custom development and manufacturingOur R D and cGMP manufacturing facilities arelocated in the US, Europe and India. We are committed to operatingour facilities with the highest standards of:Regulatory complianceEnvironmental, health and safety guidelinesCambrex Corporation is headquartered in East Rutherford, NJ, USAand is listed on the NYSE (CBM).Cambrex公司Cambrex MissionCambrex provides innovative solutions for established and emergingpharmaceutical and biotech companies with clinical or commercialAPI needs.Cambrex is an experienced supplier of small molecule products andservices to the life sciences industry.Our technologies accelerate and improve product development for ourclients.We operate within the industry’s highest quality standards, withuncompromising integrity and ethics.We have the greatest respect for our employees, the environment andthe communities in which we live and work.Cambrex公司Cambrex HistoryCambrex has positioned our product and custom development pipelinesto leverage our API, drug delivery and formulation capabilities todevelop technology advanced products. Our diverse small moleculeportfolio helps us to expand into growing developing markets andadvance our niche products and technologies.Cambrex has transformed from a fine chemical manufacturer since itscreation in 1981 and we continue to pursue acquisitions andpartnerships that improve the utilization of our manufacturingfacilities, lower our cost structure and provide access to valueadded tools or IP and low cost R D. This results inCambrex being a streamlined business with singular focus on smallmolecule therapeutics.Cambrex公司2010To broaden biocatalysis and NRT offerings to the pharmaceuticalindustry, Cambrex acquires IEP GmbH; now Cambrex IEP and ZenaraPharma, Ltd; now Cambrex Zenara.Cambrex公司2009Cambrex Karlskoga completes the addition of a new cGMP APIproduction facility.Cambrex公司2008Cambrex expands their group of world class R Dchemists by acquiring Prosyntest; renamed Cambrex Tallinn. StevenM. Klosk is appointed to CEO while remaining President. CambrexCharles City completes the addition of a high potency developmentcenter.Cambrex公司2007Cambrex exits the biologics market and re-focuses on small moleculeAPIs and intermediates at its three manufacturing facilities:Cambrex Karlskoga, Cambrex Profarmaco, and Cambrex Charles City.Cambrex Profarmaco completes the expansion of theR D lab and the additions of a new purificationdepartment and warehouse.Cambrex公司2003The company dedicates itself to providing essential products andservices that accelerate drug discovery, development andmanufacturing of human therapeutics.Cambrex公司2002To support the Companys strategic emphasis on the growingopportunities in the life sciences industry, Cambrex launches a newcorporate identity. Cambrex obtains DEA licensing for ControlledSubstance API manufacturing.Cambrex公司2001Cambrex enters the biologics manufacturing market with theacquisition of two contract biopharmaceutical manufacturingfacilities. The facilities produce purified bulk biologics andpharmaceutical ingredients from clinical to commercial scale.Cambrex公司2000Cambrex continues its growth into the life sciences and biologicsindustries through the acquisitions of a chiral enzymatic catalystbusiness and a bioscience products facility in Belgium.Cambrex公司1999Cambrex enters the growing fields of molecular biology andproteomics through the acquisition of the FMC Bioproducts business.In addition to bioscience, this acquisition further strengthens theAPI and advanced intermediates manufacturing capacity.Cambrex公司1997Cambrex enters the biologics markets with the acquisition ofBioWhittaker, a life sciences company that provides cell cultureand endotoxin detection products.Cambrex公司1994Cambrex further penetrates the pharmaceutical market with theacquisition of the Nobel Pharma Chemistry businesses, NobelChemicals AB and Profarmaco S.r.l. The business units are laterrenamed Cambrex Karlskoga and Cambrex Profarmaco.Cambrex公司1991The Company enters the life sciences arena with the acquisition ofSalsbury Chemicals, a manufacturer of bulk intermediates and APIs,as well as high-level research in nitration chemistry, and ZeelandChemicals, producer of specialty intermediates and hydrogenationchemistry.Cambrex公司1990James A. Mack is hired as President and CEO. Cambrex is listed onthe New York Stock Exchange (NYSE).Cambrex公司1987The Company changes its name to Cambrex Corporation and becomeslisted on the NASDAQ.Cambrex公司1981Originally named CasChem, the Company is founded when the castoroil and derivatives product lines are acquired from NLIndustries.Cambrex公司